

## Financial calendar 2008

Pharmexa has changed the date for Annual General Meeting from April 28, 2008 to March 31, 2008. Pharmexa's updated financial calendar is as follows:

March 3, 2008	Release of annual report for 2007
March 31, 2008	Annual General Meeting
May 9, 2008	Release of interim financial report, 1 <sup>st</sup> quarter 2008
August 21, 2008	Release of interim financial report, 2 <sup>nd</sup> quarter 2008
November 7, 2008	Release of interim financial report, 3 <sup>rd</sup> quarter 2008

Hørsholm, March 3, 2008

Jakob Schmidt  
Chief Executive Officer

### Additional information:

Jakob Schmidt, Chief Executive Officer, tel +45 4516 2525  
Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel +45 4516 2525  
or +45 4060 2558

**For the editors:** Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer and serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, arthritis, bone degeneration and Alzheimer's disease, as well as infectious diseases such as HIV, influenza, hepatitis and malaria. Company programs include GV1001, a peptide vaccine that has entered Phase III trials in pancreatic cancer and Phase II trials in liver cancer, and a number of HIV and hepatitis vaccines in Phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 80 employees and is listed on the OMX Nordic Stock Exchange Copenhagen under the trading symbol PHARMX.